Denosumab pipeline update May 2008

[chantell.reagan]

Denosumab by Amgen; expected review of postmenopausal osteoporosis (PMO) data by 2nd half of 2008
•Class/MOA: fully-human monoclonal antibody that specifically targets RANK Ligand, the essential mediator of osteoclasts
•Use: treatment of postmenopausal osteoporosis (PMO) and treatment-induced bone loss
•Dosage form: SC injection
•Link to press release:

• Amgen Press Release 4/08

•Link to clinicaltrials.gov:

• Trials registered with NIH

•Link to published studies:

• Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women -- Bone et al., 10.1210/jc.2007-2814 -- Journal of Clinical Endocrinology & Metabolism

UPDATE: The results of a Phase III study demonstrated BMD superiority compared to weekly alendronate:
Amgen press release 5/08